Molecularly-driven precision medicine for advanced bladder cancer

Laura Maria Krabbe; Vitaly Margulis; Andres Jan Schrader; Shahrokh F. Shariat; Kilian M. Gust; Martin Boegemann

doi:10.1007/s00345-018-2354-z

Molecularly-driven precision medicine for advanced bladder cancer

Laura Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, Shahrokh F. Shariat, Kilian M. Gust, Martin Boegemann

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for clinicians and patients alike. However, for the most part of the last three decades, treatment and outcomes for patients with this disease have not changed a lot. With recent advances in immunooncology leading to the approval of multiple agents for the metastatic setting, the treatment landscape started to change. With the emergent data from landmark multi-institutional sequencing projects as well as molecular data from recent trials, our understanding of the underlying disease biology, response patterns as well as definition of molecular subtypes has evolved tremendously. This review aims to summarize the currently available concepts of mutational profiles and molecular subtypes as well as their implications for management of urothelial carcinoma.

Original language	English (US)
Pages (from-to)	1749-1757
Number of pages	9
Journal	World journal of urology
Volume	36
Issue number	11
DOIs	https://doi.org/10.1007/s00345-018-2354-z
State	Published - Jan 1 2018

Keywords

Bladder cancer
Immunotherapy
Molecular profiles
Molecular subtypes
Urothelial carcinoma

ASJC Scopus subject areas

Urology

Access to Document

10.1007/s00345-018-2354-z

Cite this

@article{5bc6a98fd5a64c0581ee0d8ba23bbb4b,

title = "Molecularly-driven precision medicine for advanced bladder cancer",

abstract = "Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for clinicians and patients alike. However, for the most part of the last three decades, treatment and outcomes for patients with this disease have not changed a lot. With recent advances in immunooncology leading to the approval of multiple agents for the metastatic setting, the treatment landscape started to change. With the emergent data from landmark multi-institutional sequencing projects as well as molecular data from recent trials, our understanding of the underlying disease biology, response patterns as well as definition of molecular subtypes has evolved tremendously. This review aims to summarize the currently available concepts of mutational profiles and molecular subtypes as well as their implications for management of urothelial carcinoma.",

keywords = "Bladder cancer, Immunotherapy, Molecular profiles, Molecular subtypes, Urothelial carcinoma",

author = "Krabbe, {Laura Maria} and Vitaly Margulis and Schrader, {Andres Jan} and Shariat, {Shahrokh F.} and Gust, {Kilian M.} and Martin Boegemann",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag GmbH Germany, part of Springer Nature 2018.",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s00345-018-2354-z",

language = "English (US)",

volume = "36",

pages = "1749--1757",

journal = "World journal of urology",

issn = "0724-4983",

publisher = "Springer Verlag",

number = "11",

}

TY - JOUR

T1 - Molecularly-driven precision medicine for advanced bladder cancer

AU - Krabbe, Laura Maria

AU - Margulis, Vitaly

AU - Schrader, Andres Jan

AU - Shariat, Shahrokh F.

AU - Gust, Kilian M.

AU - Boegemann, Martin

N1 - Publisher Copyright: © Springer-Verlag GmbH Germany, part of Springer Nature 2018.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for clinicians and patients alike. However, for the most part of the last three decades, treatment and outcomes for patients with this disease have not changed a lot. With recent advances in immunooncology leading to the approval of multiple agents for the metastatic setting, the treatment landscape started to change. With the emergent data from landmark multi-institutional sequencing projects as well as molecular data from recent trials, our understanding of the underlying disease biology, response patterns as well as definition of molecular subtypes has evolved tremendously. This review aims to summarize the currently available concepts of mutational profiles and molecular subtypes as well as their implications for management of urothelial carcinoma.

AB - Urothelial carcinoma of the bladder is a heterogeneous disease with many challenges for clinicians and patients alike. However, for the most part of the last three decades, treatment and outcomes for patients with this disease have not changed a lot. With recent advances in immunooncology leading to the approval of multiple agents for the metastatic setting, the treatment landscape started to change. With the emergent data from landmark multi-institutional sequencing projects as well as molecular data from recent trials, our understanding of the underlying disease biology, response patterns as well as definition of molecular subtypes has evolved tremendously. This review aims to summarize the currently available concepts of mutational profiles and molecular subtypes as well as their implications for management of urothelial carcinoma.

KW - Bladder cancer

KW - Immunotherapy

KW - Molecular profiles

KW - Molecular subtypes

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85048292037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048292037&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2354-z

DO - 10.1007/s00345-018-2354-z

M3 - Article

C2 - 29948043

AN - SCOPUS:85048292037

SN - 0724-4983

VL - 36

SP - 1749

EP - 1757

JO - World journal of urology

JF - World journal of urology

IS - 11

ER -

Molecularly-driven precision medicine for advanced bladder cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this